MSLE Satellos Bioscience Inc.

NEUTRAL Impact: 3/10 6-K
Horizon days Filed Apr 9, 2026 Processed 1mo ago SEC 0001171843-26-002337
Notable filing: 6-K
Latest settled — T+20d
MSLE ▲ +24.19% at T+20d
NEUTRAL call ✓ call won +24.19% · α vs SPY +16.63% · entry $6.20 → $7.70
Next anchor: T+60d in 6w
Last close $6.75 (close May 22) · +8.87% from $6.20 entry
Entry anchored
Apr 8, 03:59 PM ET
via Databento tick
T+1d
+4.84%
call +4.84% · α +4.90%
$6.50
settled 6w ago
T+5d
+38.55%
call +38.55% · α +35.36%
$8.59
settled 5w ago
T+20d
+24.19%
call +24.19% · α +16.63%
$7.70
settled 17d ago
T+60d
call — · α —
in 6w

Price Chart

Loading chart...

Executive Summary

Satellos Bioscience announced it will present at the Bloom Burton & Co. Healthcare Investor Conference on April 21, 2026, where CEO Frank Gleeson will host a presentation and management will hold one-on-one meetings. This is a routine investor relations update with no new financial or clinical data disclosed.

Actionable Insight

Traders should monitor the webcast for any unexpected commentary on SAT-3247 clinical trials (BASECAMP/TRAILHEAD) or pipeline updates, but no material announcements are expected. Increased investor engagement could support sentiment ahead of future catalysts.

Key Facts

  • Satellos Bioscience (MSLE) will participate in the Bloom Burton & Co. Healthcare Investor Conference on April 21-22, 2026.
  • CEO Frank Gleeson will deliver a presentation on April 21 at 11:30 a.m. ET, and CFO Liz Williams will join one-on-one meetings.
  • The presentation will be webcast and available on the company's website, but no new clinical or financial information will be released.
  • This 6-K filing is solely to attach the press release announcing the conference participation.

Financial Impact

No immediate financial impact; presentation may improve investor visibility.

Risk Factors

  • Low attendance or lack of follow-up interest from investors could limit the event's effectiveness.
  • Failure to provide new data or guidance may result in minimal stock price movement.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-002337
Exhibit: exh_991.htm0001171843-26-002337
Document: 0001171843-26-002337-index-headers.html0001171843-26-002337
Document: 0001171843-26-002337-index.html0001171843-26-002337
Document: 0001171843-26-002337.txt0001171843-26-002337
5 reports for MSLE
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for MSLE — sortable, filterable
Type Now
May 20, 2026
3d ago
6-K
NEUTRAL ★ 2/10
awaiting T+20
May 15, 2026
8d ago
6-K
NEUTRAL ★ 5/10
awaiting T+20
May 15, 2026
8d ago
Press Release
NEUTRAL ★ 5/10
awaiting T+20
Apr 9, 2026
6w ago
6-K
NEUTRAL ★ 3/10
$6.20 $7.70▲ +24.19%▲ +16.63%$6.75 (+8.87%)
Mar 27, 2026
8w ago
6-K
BULLISH ★ 8/10
$6.19 $7.16▲ +15.67%▲ +2.93%$6.75 (+9.05%)
Showing 5 of 5

US Market Status

Market Closed — Opens Tue (34h 52m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access